Canakinumab in gout

Expert Opinion on Biological Therapy

Volumn 12, Issue 9, 2012, Pages 1265-1275

  Schlesinger, Naomi ^a  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

Canakinumab; Gout; Interleukin 1 inhibitor

Indexed keywords

ALLOPURINOL; CANAKINUMAB; COLCHICINE; CORTICOSTEROID; CRYOPYRIN; ETORICOXIB; INDOMETACIN; INTERLEUKIN 1; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE INHIBITOR; REACTIVE OXYGEN METABOLITE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RILONACEPT; TRIAMCINOLONE ACETONIDE; URATE;

ANALGESIA; APPENDICITIS; BACKACHE; BRAIN HEMORRHAGE; BRONCHITIS; CARDIOTOXICITY; CAROTID ARTERY OBSTRUCTION; DIARRHEA; DRUG BINDING; DRUG DOSE COMPARISON; DRUG FATALITY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG RESPONSE; DRUG TOLERABILITY; DRUG TOLERANCE; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL TOXICITY; GOUT; HUMAN; HYPERTENSION; INFECTION; INFLAMMATION; INJECTION SITE REACTION; LOW DRUG DOSE; LUNG EMBOLISM; NAUSEA; NEPHROTOXICITY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL; PREVALENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; VISUAL ANALOG SCALE; VOMITING;

ACUTE DISEASE; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; CHRONIC DISEASE; GOUT; GOUT SUPPRESSANTS; HALF-LIFE; HUMANS; INTERLEUKIN-1BETA; TREATMENT OUTCOME;

EID: 84865312377     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2012.705825     Document Type: Review

References (30)

1. Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum 2011;63(10):3136-41
2. Perez-Ruiz F. Treating to target: a strategy to cure gout. Rheumatology (Oxford) 2009;48(Suppl 2):ii9-ii14
3. Schlesinger N, Thiele RG. The pathogenesis of bone erosions in gouty arthritis. Ann Rheum Dis 2010;69(11):1907-12
4. Zhang W, Doherty M, Bardin T, et al. EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006;65:1312-24 (Pubitemid 44620440)
5. Jordan KM, Cameron JS, Snaith M, et al. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology 2007;46:1372-4
6. Nuki G. Colchicine: its mechanism of action and efficacy in crystal-induced inflammation. Curr Rheumatol Rep 2008;10:218-27
7. Wertheimer AI, Davis MW, Lauterio TJ. A new perspective on the pharmacoeconomics of colchicine. Curr Med Res Opin 2011;27:931-7
8. Colcrys(R) (colchicine) package insert. AR Scientific, Inc; Philadelphia, PA: 2011
9. Ahern MJ, Reid C, Gordon TP, et al. Does colchicine work? The results of the first controlled study in acute gout. Aust NZ J Med 1987;17:301-4 (Pubitemid 18014682)
10. Terkeltaub RA, Furst DE, Bennett K, et al. High versus low dosing of oral colchicine for early acute gout flare. Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum 2010;62:1060-8
11. Fam AG. Current therapy of acute microcrystalline arthritis and the role of corticosteroids. J Clin Rheumatol 1997;3:35-40 (Pubitemid 27087952)
12. Schlesinger N. Management of acute and chronic gouty arthritis: present state-of-the-art. Drugs 2004;64:2399-416 (Pubitemid 39480701)
13. Rubin BR, Burton R, Navarra S, et al. Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: a randomized controlled trial. Arthritis Rheum 2004;50:598-606 (Pubitemid 38202232)
14. Schumacher HR Jr, Boice JA, Daikh DI, et al. Randomised double blind trial of etoricoxib and indomethacin in treatment of acute gouty arthritis. Br Med J 2002;324:1488-92 (Pubitemid 34666615)
15. Schumacher HR, Chen LX. The practical management of gout. Clevel Clin J Med 2008;75(Suppl 5):S22-5
16. Eggebeen AT. Gout: an update. Am Fam Physician 2007;76:801-8.811-812
17. Cronstein BN, Terkeltaub R. The inflammatory process of gout and its treatment. Arth Res Ther 2006;8(Suppl1):S3
18. Neogi T. Gout. N Engl J Med 2011;364:443-52
19. Kineret(R) (anakinra) package insert. Biovitrum AB, Stockholm; Sweden: 2009
20. Arcalyst(R) (rilonacept) package insert. Regeneron Pharmaceuticals, Inc; Tarrytown, NY: 2010
21. Ilaris(R) (canakinumab) package insert. Novartis Pharmaceuticals Corporation; East Hanover, NJ: 2011
22. Lachmann HJ. In: Couillin I, Petrilli V, Martinon F, editors. The inflammasomes (Progress in Inflammation Research). 1st edition. Springer Basel; Basel, Switzerland: 2011. p. 209-20
23. So A, De Smedt T, Revaz S, et al. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther 2007;9:R28
24. Terkeltaub R, Sundy JS, Schumacher HR, et al. The interleukin 1 inhibitor rilonacept in the treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study. Ann Rheum Dis 2009;68:1613-17
25. Terkeltaub R, Schumacher HR, Curtis C, et al. Evaluation of rilonacept in patients with gouty arthritis experiencing an acute gout attack [abstract]. Arthritis Rheum 2010;62(Suppl 10):153
26. Schumacher HR, Sundy JS, Terkeltaub R, et al. Rilonacept (IL-1 Trap) in the prevention of acute gout flares during initiation of urate-lowering therapy: results of a phase 2 clinical trial. Arthritis Rheum 2012;64(3):876-84
27. Chakraborty A, Tannenbaum S, Rordorf C, et al. Pharmacokinetic and pharmacodynamic properties of canakinumab, a human anti-IL-1B monoclonal antibody. Clin Pharmacokinet 2012;51(6):e1-e18
28. So A, De Meulemeester M, Pikhlak A, et al. Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis. Arthritis Rheum 2010;62:3064-76
29. Schlesinger N, Lin Liao HY, De Meulemeester M, et al. Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol therapy: results of a double-blind, randomised study. Ann Rheum Dis 2011;70:1264-71
30. Schlesinger N, Alten R, Bardin T, et al. Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomized multicentre, active-controlled, double-blind trials and their initial extensions. Ann Rheum Dis 2012; Epub ahead of print